



Attorney Docket # 4948-2PCIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Carlos PICORNELL DARDER et al.

Serial No.: 09/491,624

Filed: January 26, 2000

For: Oral Pharmaceutical Preparation Comprising an
Antiulcer Activity Compound, and Process for
its Production

Group Art: 1615

I hereby certify that this correspondence is being
deposited with the United States Postal Service with
sufficient postage as first class mail in an envelope
addressed to: Assistant Commissioner for Patents,
Washington, D.C. 20231, on

August 27, 2001

(Date of Deposit)

Vincent M. Fazzari

Name of applicant, assignee or Registered Representative

Signature

August 27, 2001

Date of Signature

REQUEST FOR CORRECTION OF FILING RECEIPT

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

Attached is a copy of the official filing receipt received from the U.S. Patent and
Trademark Office in the above-identified application.

There is an error in:

- ☐ Applicants' name and/or address
- ☐ Title
- ☐ Filing Date
- ☐ Serial Number
- ☒ Priority Data (number)
- ☐ Incorrect Priority Date
- ☐ Other [pls specify]

which should read as follows: PCT PCT/ES98/00204 7/13/98 Spain P 9900157 1/27/99

It is respectfully requested that a corrected filing receipt be issued.

Respectfully submitted,
COHEN, PONTANI, LIEBERMAN & PAVANE

By: 

Vincent M. Fazzari

Reg. No. 26,879

551 Fifth Avenue, Suite 1210

New York, New York 10176

(212) 687-2770

Dated: August 27, 2001

FILING RECEIPT



OC000000005001469

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

RECEIVED
 SEP 10 2000
 TECO CENTER 1600/2900

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/491,624	01/26/2000	1615	462	4948-2PCIP	8	33	2

Thomas C. Pontani Esquire
 Cohen Pontani Lieberman & Pavane
 551 Fifth Avenue Suite 1210
 New York, NY 10176

Date Mailed: 03/21/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Carlos Picornell Darder, Madrid, SPAIN;

Continuing Data as Claimed by Applicant

Foreign Applications

SPAIN P 9701816 07/31/1997
 PCT PCT/ES98/00204 01/27/1999

COHEN, PONTANI, LIEBERMAN & PAVANE

MAR 9 4 2000

If Required, Foreign Filing License Granted 03/21/2000

RECEIVED

** SMALL ENTITY **

Title

Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production

Preliminary Class

424

Data entry by : HINES, BRENDA

Team : OIPE

Date: 03/21/2000





**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

RECEIVED
SEP 10 2001
TECH CENTER 1600/2600

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

FILE COPY

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 8816

SERIAL NUMBER 09/491,624	FILING DATE 01/26/2000 RULE	CLASS 424	GROUP ART UNIT 1615	ATTORNEY DOCKET NO. 4948-2PCIP
------------------------------------	-------------------------------------------------	---------------------	-------------------------------	------------------------------------------

APPLICANTS

Carlos Picornell Darder, Madrid, SPAIN;

**** CONTINUING DATA *********** FOREIGN APPLICATIONS *******

PCT/ES98/00204 07/13/1998

SPAIN P 9900157 01/27/1999

IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** SMALL ENTITY ****** 03/21/2000**

Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY SPAIN	SHEETS DRAWING 8	TOTAL CLAIMS 33	INDEPENDENT CLAIMS 2
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged	Examiner's Signature	Initials		

ADDRESS

THOMAS C. PONTANI, ESQ.
COHEN PONTANI LIEBERMAN & PAVANE
551 FIFTH AVENUE
SUITE 1210
NEW YORK, NY 10176

TITLE

Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production

FILING FEE RECEIVED 462	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit